Johnson & Johnson, a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of senior unsecured notes. The notes, offered in various denominations and maturities, will pay interest semiannually and are expected to rank equally with the company's other unsecured and unsubordinated debt. The prospectus supplement, dated May 13, 2024, is part of an effective registration statement filed with the SEC and is not an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. The notes will be issued in minimum denominations of $2,000 with additional increments of $1,000. Johnson & Johnson may redeem the notes at any time...Show More

Johnson & Johnson, a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of senior unsecured notes. The notes, offered in various denominations and maturities, will pay interest semiannually and are expected to rank equally with the company's other unsecured and unsubordinated debt. The prospectus supplement, dated May 13, 2024, is part of an effective registration statement filed with the SEC and is not an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. The notes will be issued in minimum denominations of $2,000 with additional increments of $1,000. Johnson & Johnson may redeem the notes at any time, subject to certain conditions. The underwriters for the offering are J.P. Morgan, BofA Securities, and Citigroup. The proceeds from the offering are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to shareholder and regulatory approvals. The offering is expected to close on or about a date to be announced in 2024.